Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary Protein Oral Delivery (POD) technology for the delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching a Phase 2b multi-center trial under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.

In the News

May Issue - Diabetes Forecast: What’s Next for Insulin: No Needles? Read here.
 
For more on Oramed in the news, click here.
 
Press Releases

December 3, 2014

Oramed Closes $5 Million Investment from Guangxi Wuzhou Pharmaceutical Company

...read more>>

 

December 2, 2014

Oramed Pharmaceuticals at LD MICRO "Main Event" Micro-Cap Growth Conference on December 2, 2014 

...read more>>

 

 

November 2, 2014

Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insluin in Type 1 Diabetes

...read more>>

 

 

October 26, 2014

Oramed to Present at the FireRock Annual Micro-Cap Conference 

...read more>>

 

 

October 22, 2014

Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insluin in Type 1 Diabetes

...read more>>

 

 

September 5, 2014

Oramed to Present at Family Office & Wealth Management Conference

...read more>>

 

 

September 3, 2014

Oramed to Present at Upcoming Conferences

...read more>>

 

 

 

 
Press Center | Terms & Conditions | Privacy Statement Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed